Latest Vertex Pharmaceuticals News & Updates

See the latest news and media coverage for Vertex. We track all announcements, press releases, and industry mentions in real time, all in one place.

Vertex Pharmaceuticals (Vertex)

Biopharmaceutical company

vrtx.com

Headquarters: Boston, United States
Founded year: 1989
Company type: Public company
Number of employees: 6,000–10,000
Industry: Pharmaceuticals

Last updated Today

Latest news about Vertex Pharmaceuticals (Vertex)

In short: Vertex expanded the reach of its CRISPR gene therapy Casgevy, executed a $10 billion acquisition of Crinetics, and posted strong Q1 growth.

Company announcements

July 9 Vertex

Vertex celebrates FDA approval for CRISPR therapy

The therapy targets sickle cell disease and beta thalassemia in children, with associates instrumental in its development.

July 6 Vertex

Vertex acquires Crinetics Pharmaceuticals for $10 billion

The acquisition adds potential best-in-class endocrinology assets with $5 billion peak sales opportunity.

July 1 Vertex

Vertex receives FDA approval for CASGEVY in children ages 2 and older

The approval adds approximately 5,500 eligible children in the US, expanding from prior approval for ages 12 and older.

June 11 Vertex

Vertex presents new CASGEVY data in children 5–11

Data from pivotal studies show transformative potential consistent with older patients; regulatory submissions made in US, Saudi Arabia, and UK.

Media coverage

July 29 STAT

Ending the Pharma Relay Race with a Non-Opioid Breakthrough | PharmExec

A fragmented approach to drug discovery created structural inefficiencies that drive up R&D costs.

Never miss news about Vertex

Track Vertex and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Vertex competitors & trending companies

Browse news for competitors to Vertex and other trending companies.